BACKGROUND: Interleukin-10 (IL-10) is a potent immunoregulatory cytokine. IL-10-promoter polymorphisms have been shown to affect human immunodeficiency virus type 1 (HIV-1) clinical outcomes but the underlying mechanisms are poorly understood. METHODS: We investigated the relationship between IL-10-promoter variants, plasma cytokine levels, immune responses and markers of disease outcome in antiretroviral-naïve HIV-1 chronically infected individuals from South Africa. Two IL-10-promoter single nucleotide polymorphisms (SNPs) were genotyped in 451 participants. Baseline plasma levels of select cytokines were measured for 112 individuals. Viral load, CD4(+) T-cell counts and HIV-1-specific interferon-gamma CD8(+) T-cell immune responses were measured at baseline. CD4(+) T-cell counts were measured longitudinally and rates of CD4(+) T-cell decline computed for 300 study subjects. RESULTS: The minor IL-10-1082G and -592A variants occurred at frequencies of 0.31 and 0.34, respectively. The -592AA genotype associated significantly with attenuated loss of CD4(+) T cells (P = .0496). Individuals possessing -1082GG had significantly higher IL-10 levels compared to -1082AA/AG (P = .0006). The -592AA genotype was associated with greater breadth of virus-specific CD8(+) T-cell responses compared to CC and CA (P = .002 and .004 respectively). CONCLUSIONS: IL-10-promoter variants may influence the rate of HIV-1 disease progression by regulating IL-10 levels and the breadth of CD8(+) T-cell immune responses.
BACKGROUND:Interleukin-10 (IL-10) is a potent immunoregulatory cytokine. IL-10-promoter polymorphisms have been shown to affect human immunodeficiency virus type 1 (HIV-1) clinical outcomes but the underlying mechanisms are poorly understood. METHODS: We investigated the relationship between IL-10-promoter variants, plasma cytokine levels, immune responses and markers of disease outcome in antiretroviral-naïve HIV-1 chronically infected individuals from South Africa. Two IL-10-promoter single nucleotide polymorphisms (SNPs) were genotyped in 451 participants. Baseline plasma levels of select cytokines were measured for 112 individuals. Viral load, CD4(+) T-cell counts and HIV-1-specific interferon-gamma CD8(+) T-cell immune responses were measured at baseline. CD4(+) T-cell counts were measured longitudinally and rates of CD4(+) T-cell decline computed for 300 study subjects. RESULTS: The minor IL-10-1082G and -592A variants occurred at frequencies of 0.31 and 0.34, respectively. The -592AA genotype associated significantly with attenuated loss of CD4(+) T cells (P = .0496). Individuals possessing -1082GG had significantly higher IL-10 levels compared to -1082AA/AG (P = .0006). The -592AA genotype was associated with greater breadth of virus-specific CD8(+) T-cell responses compared to CC and CA (P = .002 and .004 respectively). CONCLUSIONS:IL-10-promoter variants may influence the rate of HIV-1 disease progression by regulating IL-10 levels and the breadth of CD8(+) T-cell immune responses.
Authors: Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld Journal: J Clin Invest Date: 2010-05-03 Impact factor: 14.808
Authors: A Vasilescu; S C Heath; R Ivanova; H Hendel; H Do; A Mazoyer; E Khadivpour; F X Goutalier; K Khalili; J Rappaport; G M Lathrop; F Matsuda; J-F Zagury Journal: Genes Immun Date: 2003-09 Impact factor: 2.676
Authors: P J Goulder; M M Addo; M A Altfeld; E S Rosenberg; Y Tang; U Govender; N Mngqundaniso; K Annamalai; T U Vogel; M Hammond; M Bunce; H M Coovadia; B D Walker Journal: J Virol Date: 2001-02 Impact factor: 5.103
Authors: L G Kostrikis; A U Neumann; B Thomson; B T Korber; P McHardy; R Karanicolas; L Deutsch; Y Huang; J F Lew; K McIntosh; H Pollack; W Borkowsky; H M Spiegel; P Palumbo; J Oleske; A Bardeguez; K Luzuriaga; J Sullivan; S M Wolinsky; R A Koup; D D Ho; J P Moore Journal: J Virol Date: 1999-12 Impact factor: 5.103
Authors: Alexandra Y Soare; Natasha D Durham; Ramya Gopal; Benjamin Tweel; Kevin W Hoffman; Julia A Brown; Megan O'Brien; Nina Bhardwaj; Jean K Lim; Benjamin K Chen; Talia H Swartz Journal: J Virol Date: 2018-12-10 Impact factor: 5.103
Authors: Anabela C P Picton; Maria Paximadis; Gemma W Koor; Avani Bharuthram; Sharon Shalekoff; Ria Lassauniere; Prudence Ive; Caroline T Tiemessen Journal: Front Immunol Date: 2021-12-20 Impact factor: 7.561
Authors: Djeneba Dabitao; Mamadou Dembele; Michael Urbanowski; Bourahima Kone; Mamadou Wague; Nadie Coulibaly; Yeya Dit Sadio Sarro; Bocar Baya; Drissa Goita; Sounkalo Dao; Michael Belson; Sabra L Klein; Chad Achenbach; Jane L Holl; Mahamadou Diakite; Seydou Doumbia; Jay H Bream; William R Bishai; Souleymane Diallo; Robert L Murphy Journal: AIDS Res Hum Retroviruses Date: 2020-11-23 Impact factor: 2.205